Zealand Pharma, which is developing peptide-based treatments for type 2 diabetes, filed on Thursday with the SEC to raise up to $86 million in a US initial public offering. The company has traded in Denmark on the Nasdaq Copenhagen under the symbol ZEAL since 2010.
The Glostrup, Denmark-based company was founded in 1997 and booked $47 million in revenue for the 12 months ended March 31, 2017. It plans to list on the Nasdaq under the symbol ZLND. Zealand Pharma filed confidentially on June 16, 2016. Morgan Stanley and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
